Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tenax Therapeutics Inc. (TENX:NASDAQ), powered by AI.
Tenax Therapeutics Inc. is currently trading at $11.33. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Tenax Therapeutics Inc. on Alpha Lenz.
Tenax Therapeutics Inc.'s P/E ratio is -8.4.
“Tenax Therapeutics Inc. trades at a P/E of -8.4 (undervalued) with modest ROE of -55.6%.”
Ask for details →Tenax Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing products for the critical care market. The primary function of Tenax Therapeutics is to develop clinical-stage treatments in areas such as cardiopulmonary diseases. One of the notable features of the company is its dedication to researching and advancing therapies to address significant unmet medical needs, particularly through innovative drug development. Tenax Therapeutics has been part of the critical care segment, working on potential treatments that could have a substantial impact on patients with severe cardiovascular and pulmonary conditions. The firm's activities in novel drug formulations and clinical trials contribute to its role in the biopharmaceutical landscape, aiming to bring new hope and innovative therapies to markets with limited options. Based in the United States, Tenax Therapeutics continues to push forward in the field of healthcare, leveraging scientific research and pharmaceutical advancements to impact the lives of patients and the broader healthcare community significantly.
“Tenax Therapeutics Inc. trades at a P/E of -8.4 (undervalued) with modest ROE of -55.6%.”
Ask for details →Tenax Therapeutics Inc. (ticker: TENX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 4 employees. Market cap is $444M.
The current price is $11.33 with a P/E ratio of -8.45x and P/B of 4.58x.
ROE is -55.64%.